Skip to main content

Table 5 Extent of exposure and tolerability assessments, treated set

From: Treatment of acute rhinitis with a nasal spray containing tramazoline and essential oils: a multicenter, uncontrolled, observational trial

 

Children

Adolescents

Adults

Total

Patients, N (%)

108 (36.0)

30 (10.0)

162 (54.0)

300 (100)

Exposure to trial medication

 Mean days of exposure to trial drug (SD)

7.1 (1.3)

6.8 (1.4)

7.2 (1.8)

7.1 (1.6)

 Median days of exposure to trial drug

7

6

7

7

 Minimum

4

5

3

3

 Maximum

10

9

12

12

Patients’ tolerability assessment, N (%)

 Very good

100 (92.6)

25 (83.3)

105 (64.8)

236 (78.7)

 Good

7 (6.5)

5 (16.7)

50 (30.9)

64 (21.3)

 Fair

1 (0.9)

0 (0.0)

6 (3.7)

7 (2.3)

 Poor

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Missing

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Investigators’ tolerability assessment, N (%)

 Very good

101 (93.6)

26 (86.7)

109 (67.3)

236 (78.7)

 Good

7 (6.5)

4 (13.3)

53 (32.7)

64 (21.3)

 Fair

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Poor

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)